Conference Coverage: ASCO 2024 – Focus on Genitourinary (GU) Malignancies
Impact of recent ASCO data on clinical practice and therapy guidance in GU cancers
FACULTY MEMBERS
Terence Friedlander, MD
University of California, San Francisco, CA, USA
Mark Tyson, MD, MPH
Mayo Clinic, Phoenix, AZ, USA
David Crawford, MD
University of California, San Diego, CA, USA
Scott Tagawa, MD, FACP, FASCO
Weill Cornell Medicine, New York, NY, USA
Joaquim Bellmunt, MD, PhD
Harvard Medical School, Boston, MA, USA
Thomas Powles, MBBS, MRCP, MD
Barts Cancer Institute, London, UK
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Bladder Cancer – Non–Muscle-Invasive Disease
- Bladder Cancer – Muscle-Invasive Disease
- Bladder Cancer – Advanced/Metastatic Disease
- Prostate Cancer – Hormonal, Cytotoxic, and Targeted Therapies
- Prostate Cancer – Radioligands
